BioCardia, Inc.
Nasdaq · Biological Products, (No Diagnostic Substances)
Company Overview
A concise company profile alongside the latest public filing activity.
BioCardia develops cell and biologic therapies for cardiovascular and pulmonary diseases, including its CardiAMP and CardiALLO cell therapy platforms and Helix biotherapeutic delivery system, which are being tested in clinical trials for conditions such as heart failure and pulmonary hypertension.
Company profile sourced from SEC filings.
Corporate Insider Trades
Open-market purchases and sales by directors, officers, and other company insiders.
| Insider | Type | Value | Shares / Price | Date |
|---|---|---|---|---|
| Altman PeterPresident and CEO | Buy | $872 | 800at $1.09 | Sep 3, 2026 |
| Altman PeterPresident and CEO | Buy | $5K | 5,400at $0.93 | Aug 17, 2026 |
Source: SEC EDGAR Form 4 filings
Congressional Trades
Recent disclosures by members of the U.S. House and Senate.
Source: Senate eFD and House Clerk STOCK Act disclosures
Get notable BCDA activity by email
Free alerts for the insider and congressional trades worth watching.
For informational purposes only, not investment advice. Filings can be delayed, corrected, or amended. Trading activity alone does not predict future performance.